The various HIV “cures” and vaccines in development continue to speed ahead, with one pharmaceutical company’s product advancing into stage 2 human clinical trials.
“We are delighted to be able to open these two important clinical studies ahead of schedule,” said Geoff Nichol, M.B. Ch.B., Sangamo’s executive vice president, research and development. “Data from earlier Phase 1 trials demonstrated a statistically significant relationship between the number of circulating T-cells in which both CCR5 genes are modified and the reduction in HIV viral load in infected subjects during an interruption of anti-retroviral therapy. Both of these new Phase 2 clinical trials are specifically designed to confirm and further investigate these findings.”
The new studies employ two approaches to increase the number of engrafted T-cells in which both CCR5 gene copies are modified (biallelically modified) in SB-728-T-treated, HIV-infected subjects. The first, an extension of an ongoing trial (SB-728-902, Cohort 5), is designed to further investigate the effect of SB-728-T treatment on HIV viral load in subjects that are naturally heterozygous for the CCR5 delta-32 gene mutation (i.e. one of their two CCR5 gene copies has the mutation and one is normal).
The second study (SB-728-1101), in HIV-infected subjects without the CCR5 delta-32 mutation, employs a conditioning pretreatment designed to significantly enhance the number of engrafted biallelically modified T-cells.